Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
|Articles|June 27, 2023
Pointers With Portela: Reviewing Micro-Needling, Retinol, and Sunscreen
Author(s)Dustin Portela, DO
In this week’s Pointers With Portela, the 208SkinDoc reviews questions from social media about micro-needling, retinol, and sunscreen use.
Advertisement
- How often should you do micro-needling?
- When can I start using retinol?
- What time of day should I stop applying sunscreen?
Questions can be submitted via Portela's
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Advertisement
Related to this article
Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.
Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.
BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.
A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.
The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.
Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.
Advertisement
Advertisement
Trending on Dermatology Times
1
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
2
PASI 100 Rates and Site-Specific Responses With Oral Psoriasis Therapies
3
Bimekizumab Sustains Joint Responses Through Week 24 in PsA
4
Litifilimab Improves Cutaneous Lupus Symptoms Through 52 Weeks
5